Cost Containment for Treating Hypertension in African Americans: Impact of a Combined ACE Inhibitor-calcium Channel Blocker

Journal of the National Medical Association

Volumn 89, Issue 7, 1997, Pages 457-460

  Kountz, David S ^a,b  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b NONE   (United States)

Author keywords

ACE inhibitor; African Americans; Calcium channel blocker; Hypertension

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; BENZAZEPINE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTICLE; COST CONTROL; DRUG COMBINATION; DRUG COST; ECONOMICS; HEALTH INSURANCE; HUMAN; HYPERTENSION; MEDICAID; NEGRO; PATIENT COMPLIANCE; PHARMACOKINETICS; UNITED STATES;

AFRICAN CONTINENTAL ANCESTRY GROUP; AMLODIPINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BENZAZEPINES; CALCIUM CHANNEL BLOCKERS; COST CONTROL; COST SAVINGS; DRUG COMBINATIONS; DRUG COSTS; HUMANS; HYPERTENSION; MANAGED CARE PROGRAMS; MEDICAID; PATIENT COMPLIANCE; THERAPEUTIC EQUIVALENCY; UNITED STATES;

EID: 0031183059     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Elliott WJ. The cost of treating hypertension. Postgrad Med. 1996;99:241-252.
2. Manolio TA, Cutler JA, Furberg CD, Psaty BM, Whelton PK, Applegate WB. Trends in pharmacologic management of hypertension in the United States. Arch Intern Med. 1995;155:829-837.
3. Hall WD, Kong W. Hypertension in blacks: nonpharmacologic and pharmacologic therapy, In: Saunders E, ed. Cardiovascular Diseases in Blacks. Philadelphia, Pa: FA Davis Co; 1991:157-169.
4. Brouwer RML, Bolli P, Erne P, Conen D, Kiowski W, Buhler FR. Antihypertensive treatment using calcium antagonists in combination with captopril rather than diuretics. J Cardiovasc Pharmacol. 1985;7:S88-S91.
5. Reif MC, Carter VL. The retail cost of antihypertensive therapy. Am J Hypertens. 1994;7:571-575.
6. Soumerai SB, Ross-Degnan D, Avorn J, McLaughlin TJ, Choodnovskly I. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. N Engl J Med. 1991;325:1072-1077.
7. Fingl E, Woodbury DM. General principles. In: Goodman LS, Gilman A, eds. The Pharmacologic Basis of Therapeutics. 4th ed. New York, NY: Macmillan; 1970:24-25.
8. Brown SA, Walton CL, Crawford P, Bakris GL. Long-term effects of antihypertensive regimens on renal hemodynamics and proteinuria. Kidney Int. 1993;43:1210-1218.
9. Saunders E, Weir MR, Kong BW, Hollifield J, Gray J, Vertes V, et al. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med. 1990;150:1707-1713.
10. Materson BJ, Reda DJ, Cushman WC, Massie BM, Fries ED, Kochar MS, et al. Single drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med. 1993;328:914-921.
11. Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR, et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation. 1994;90:2056-2069.
12. Holland OB, von Kuhnert L, Campbell WB, Anderson RJ. Synergistic effect of captopril with hydrochlorothiazide for treatment of low-renin hypertension in black patients. Hypertension. 1983;5:235-239.